TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Net Income
Bottom-line profit after all expenses, interest, and taxes.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $1.54M, compared with -$10.38M a year earlier. Trailing-twelve-month net income was -$27.31M.
Context
- Net income amounted to 86.9% of revenue in FY2025, down 26.0 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$16.56M (+57.8%) for the fiscal year ending Dec 2026, a step up from the -18.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.54M+115.8% QoQ
- Last fiscal yearDec 2025
- -$39.23M-18.0% YoY
- LTMMar 2026
- -$27.31M-0.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +114.8% | -9.4% | -124.2 pp |
| 1 year | -18.0% | +57.8% | +75.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (39.23M) USD
- Year-over-year change
- -18.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (39.23M) | -18.0% |
| FY2024 | 2024-12-31 | (33.23M) | +44.0% |
| FY2023 | 2023-12-31 | (59.36M) | -25.8% |
| FY2022 | 2022-12-31 | (47.19M) | -63.6% |
| FY2021 | 2021-12-31 | (28.85M) | — |
Net Income vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 net income of -$27.31M is the 2nd highest of the 11 companies compared; the peer median is -$58.54M.
- Its year-over-year change of -0.4% is the 4th highest of 11, against a peer median of -25.9%.
- Net income amounts to 60.9% of revenue for TLSI, versus a peer median of 164.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.4M | +151.9% | — | 50.9% | |
| LTM Mar 2026 | -$27.31M | -0.4% | — | 60.9% | |
| LTM Mar 2026 | -$37.11M | +23.5% | — | 24.5% | |
| LTM Mar 2026 | -$39.12M | +6.4% | — | 121.2% | |
| LTM Mar 2026 | -$39.2M | -21.3% | — | 207.7% | |
| LTM Mar 2026 | -$46.04M | -260.1% | — | 43.0% | |
| LTM Mar 2026 | -$71.04M | -47.6% | — | 62.5% | |
| LTM Dec 2025 | -$75.02M | -40.2% | — | 576.1% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -$95.3M | -16.5% | — | 5148.8% |
| LTM Mar 2026 | -$111.13M | -30.5% | — | 17982.7% | |
| LTM Mar 2026 | -$282.61M | -66241.3% | — | 9554.2% | |
| Peer median (excluding TLSI) | -$58.54M | -25.9% | — | 164.4% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.